117 related articles for article (PubMed ID: 36440599)
21. Smart aptamer-modified calcium carbonate nanoparticles for controlled release and targeted delivery of epirubicin and melittin into cancer cells in vitro and in vivo.
Yazdian-Robati R; Arab A; Ramezani M; Rafatpanah H; Bahreyni A; Nabavinia MS; Abnous K; Taghdisi SM
Drug Dev Ind Pharm; 2019 Apr; 45(4):603-610. PubMed ID: 30633594
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of tumor metastasis by targeted daunorubicin and dioscin codelivery liposomes modified with PFV for the treatment of non-small-cell lung cancer.
Wang Y; Fu M; Liu J; Yang Y; Yu Y; Li J; Pan W; Fan L; Li G; Li X; Wang X
Int J Nanomedicine; 2019; 14():4071-4090. PubMed ID: 31239668
[No Abstract] [Full Text] [Related]
23. Pharmacokinetics and antitumor activity of epirubicin encapsulated in long-circulating liposomes incorporating a polyethylene glycol-derivatized phospholipid.
Mayhew EG; Lasic D; Babbar S; Martin FJ
Int J Cancer; 1992 May; 51(2):302-9. PubMed ID: 1568796
[TBL] [Abstract][Full Text] [Related]
24. The anti-ovarian cancer effect of RPV modified paclitaxel plus schisandra B liposomes in SK-OV-3 cells and tumor-bearing mice.
Zhang L; Kong L; He SY; Liu XZ; Liu Y; Zang J; Ju RJ; Li XT
Life Sci; 2021 Nov; 285():120013. PubMed ID: 34614418
[TBL] [Abstract][Full Text] [Related]
25. HER2-Specific Reduction-Sensitive Immunopolymersomes with High Loading of Epirubicin for Targeted Treatment of Ovarian Tumor.
Ding L; Gu W; Zhang Y; Yue S; Sun H; Cornelissen JJLM; Zhong Z
Biomacromolecules; 2019 Oct; 20(10):3855-3863. PubMed ID: 31513391
[TBL] [Abstract][Full Text] [Related]
26. Tuftsin-Bearing Liposomes Co-Encapsulated with Doxorubicin and Curcumin Efficiently Inhibit EAC Tumor Growth in Mice.
Murugesan K; Srinivasan P; Mahadeva R; Gupta CM; Haq W
Int J Nanomedicine; 2020; 15():10547-10559. PubMed ID: 33414637
[TBL] [Abstract][Full Text] [Related]
27. Efficient siRNA Delivery by Lipid Nanoparticles Modified with a Nonstandard Macrocyclic Peptide for EpCAM-Targeting.
Sakurai Y; Mizumura W; Murata M; Hada T; Yamamoto S; Ito K; Iwasaki K; Katoh T; Goto Y; Takagi A; Kohara M; Suga H; Harashima H
Mol Pharm; 2017 Oct; 14(10):3290-3298. PubMed ID: 28789523
[TBL] [Abstract][Full Text] [Related]
28. FRET-trackable biodegradable HPMA copolymer-epirubicin conjugates for ovarian carcinoma therapy.
Yang J; Zhang R; Radford DC; Kopeček J
J Control Release; 2015 Nov; 218():36-44. PubMed ID: 26410808
[TBL] [Abstract][Full Text] [Related]
29. Curcumin-loaded liposomes modulating the synergistic role of EpCAM and estrogen receptor alpha in lung cancer management.
Singh M; De Rubis G; Kokkinis S; Paudel KR; Yeung S; Hansbro PM; Oliver BGG; Dua K
Pathol Res Pract; 2024 May; 257():155317. PubMed ID: 38657558
[TBL] [Abstract][Full Text] [Related]
30. Destruction of vasculogenic mimicry channels by targeting epirubicin plus celecoxib liposomes in treatment of brain glioma.
Ju RJ; Zeng F; Liu L; Mu LM; Xie HJ; Zhao Y; Yan Y; Wu JS; Hu YJ; Lu WL
Int J Nanomedicine; 2016; 11():1131-46. PubMed ID: 27042063
[TBL] [Abstract][Full Text] [Related]
31. Effect of phospholipid composition on pharmacokinetics and biodistribution of epirubicin liposomes.
Sha X; Guo J; Chen Y; Fang X
J Liposome Res; 2012 Mar; 22(1):80-8. PubMed ID: 22022836
[TBL] [Abstract][Full Text] [Related]
32. Double targeting and aptamer-assisted controlled release delivery of epirubicin to cancer cells by aptamers-based dendrimer in vitro and in vivo.
Taghdisi SM; Danesh NM; Ramezani M; Lavaee P; Jalalian SH; Robati RY; Abnous K
Eur J Pharm Biopharm; 2016 May; 102():152-8. PubMed ID: 26987703
[TBL] [Abstract][Full Text] [Related]
33. Multifunctional Targeting Liposomes of Epirubicin Plus Resveratrol Improved Therapeutic Effect on Brain Gliomas.
Kong D; Hong W; Yu M; Li Y; Zheng Y; Ying X
Int J Nanomedicine; 2022; 17():1087-1110. PubMed ID: 35313461
[TBL] [Abstract][Full Text] [Related]
34. Effects of surface charge of low molecular weight heparin-modified cationic liposomes on drug efficacy and toxicity.
Li H; Chen Y; Deng Y; Wang Y; Ke X; Ci T
Drug Dev Ind Pharm; 2017 Jul; 43(7):1163-1172. PubMed ID: 28277844
[TBL] [Abstract][Full Text] [Related]
35. Improved antitumor activity and reduced cardiotoxicity of epirubicin using hepatocyte-targeted nanoparticles combined with tocotrienols against hepatocellular carcinoma in mice.
Nasr M; Nafee N; Saad H; Kazem A
Eur J Pharm Biopharm; 2014 Sep; 88(1):216-25. PubMed ID: 24813390
[TBL] [Abstract][Full Text] [Related]
36. Development of targeting lonidamine liposomes that circumvent drug-resistant cancer by acting on mitochondrial signaling pathways.
Li N; Zhang CX; Wang XX; Zhang L; Ma X; Zhou J; Ju RJ; Li XY; Zhao WY; Lu WL
Biomaterials; 2013 Apr; 34(13):3366-80. PubMed ID: 23410681
[TBL] [Abstract][Full Text] [Related]
37. Arginine, glycine, aspartic acid peptide-modified paclitaxel and curcumin co-loaded liposome for the treatment of lung cancer: in vitro/vivo evaluation.
Jiang K; Shen M; Xu W
Int J Nanomedicine; 2018; 13():2561-2569. PubMed ID: 29731631
[TBL] [Abstract][Full Text] [Related]
38. The Use of a Liposomal Formulation Incorporating an Antimicrobial Peptide from Tilapia as a New Adjuvant to Epirubicin in Human Squamous Cell Carcinoma and Pluripotent Testicular Embryonic Carcinoma Cells.
Lo YL; Lee HP; Tu WC
Int J Mol Sci; 2015 Sep; 16(9):22711-34. PubMed ID: 26393585
[TBL] [Abstract][Full Text] [Related]
39. Transferrin and octaarginine modified dual-functional liposomes with improved cancer cell targeting and enhanced intracellular delivery for the treatment of ovarian cancer.
Deshpande P; Jhaveri A; Pattni B; Biswas S; Torchilin V
Drug Deliv; 2018 Nov; 25(1):517-532. PubMed ID: 29433357
[TBL] [Abstract][Full Text] [Related]
40. Surface-modified Epirubicin-HCl liposomes and its in vitro assessment in breast cancer cell-line: MCF-7.
Gandhi R; Khatri N; Baradia D; Vhora I; Misra A
Drug Deliv; 2016 May; 23(4):1152-62. PubMed ID: 25586675
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
